Method of regulating glucose metabolism, and reagents related thereto
DCFirst Claim
1. A method for treating Type II diabetes, comprising administering orally to an animal in need thereof a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof once daily, wherein the inhibitor has a Ki for inhibition of DPIV of 10 nM or less;
- the duration of the therapeutic effect is at least about 24 hours; and
the inhibitor is administered in an amount sufficient to treat Type II diabetes but not sufficient to suppress the immune system of the animal.
6 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.
20 Citations
30 Claims
-
1. A method for treating Type II diabetes, comprising administering orally to an animal in need thereof a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof once daily, wherein the inhibitor has a Ki for inhibition of DPIV of 10 nM or less;
- the duration of the therapeutic effect is at least about 24 hours; and
the inhibitor is administered in an amount sufficient to treat Type II diabetes but not sufficient to suppress the immune system of the animal.
- the duration of the therapeutic effect is at least about 24 hours; and
-
2. The method of claim 1, wherein the inhibitor has a Ki for inhibition of DPIV of 1.0 nM or less.
-
3. The method of claim 2, wherein the inhibitor has a Ki for inhibition of DPIV of 0.1 nM or less.
-
4. The method of claim 3, wherein the inhibitor has a Ki for inhibition of DPIV of 0.01 nM or less.
-
5. The method of claim 1, wherein the inhibitor has an EC50 for treatment of Type II diabetes at least one order of magnitude less than its EC50 for immunosuppression.
-
6. The method of claim 5, wherein the inhibitor has an EC50 for treatment of Type II diabetes at least two orders of magnitude less than its EC50 for immunosuppression.
-
7. The method of claim 1, wherein the inhibitor has a molecular weight less than 5000 amu.
-
8. The method of claim 7, wherein the inhibitor has a molecular weight less than 2000 amu.
-
9. The method of claim 8, wherein the inhibitor has a molecular weight less than 1000 amu.
-
10. The method of claim 1, wherein the animal is a mammal.
-
11. The method of claim 10, wherein the mammal is a human.
-
12. The method of claim 1, wherein the inhibitor is administered in a solid dosage form.
-
13. The method of claim 12, wherein the solid dosage form is a tablet, capsule or pill.
-
14. The method of claim 12, wherein the solid dosage form is a tablet.
-
15. The method of claim 14, wherein the solid dosage form is a coated tablet.
-
16. The method of claim 1, wherein the duration of the therapeutic effect is about 24 hours.
-
17. The method of claim 1, wherein the animal is a human;
- and the duration of the therapeutic effect is about 24 hours.
-
18. The method of claim 1, wherein the animal is a human;
- and the inhibitor has a molecular weight less than 1000 amu.
-
19. The method of claim 1, wherein the animal is a human;
- and the inhibitor is administered in the form of a tablet, capsule or pill.
-
20. The method of claim 1, wherein the animal is a human;
- and the inhibitor is administered in the form of a tablet.
-
21. The method of claim 1, wherein the animal is a human;
- and the inhibitor is administered in the form of a coated tablet.
-
22. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet, capsule or pill; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a tablet, capsule or pill; and
-
23. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a tablet; and
-
24. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a coated tablet; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a coated tablet; and
-
25. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet, capsule or pill; and
the duration of the therapeutic effect is about 24 hours.
- the inhibitor is administered in the form of a tablet, capsule or pill; and
-
26. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet; and
the duration of the therapeutic effect is about 24 hours.
- the inhibitor is administered in the form of a tablet; and
-
27. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a coated tablet; and
the duration of the therapeutic effect is about 24 hours.
- the inhibitor is administered in the form of a coated tablet; and
-
28. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet, capsule or pill;
the duration of the therapeutic effect is about 24 hours; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a tablet, capsule or pill;
-
29. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a tablet;
the duration of the therapeutic effect is about 24 hours; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a tablet;
-
30. The method of claim 1, wherein the animal is a human;
- the inhibitor is administered in the form of a coated tablet;
the duration of the therapeutic effect is about 24 hours; and
the inhibitor has a molecular weight less than 1000 amu.
- the inhibitor is administered in the form of a coated tablet;
Specification